Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
25%
Ph early_phase_1
2
50%
Ph phase_2
1
25%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
2(50.0%)
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Completed(1)

Detailed Status

Active, not recruiting2
Completed1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 12 (50.0%)
Phase 11 (25.0%)
Phase 21 (25.0%)

Trials by Status

active_not_recruiting250%
completed125%
not_yet_recruiting125%

Recent Activity

2 active trials
Showing 4 of 4
not_yet_recruitingphase_2

CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer

NCT07543172
completedearly_phase_1

A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

NCT04298606
active_not_recruitingearly_phase_1

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

NCT06011772
active_not_recruitingphase_1

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

NCT02955290

Clinical Trials (4)

Showing 4 of 4 trials
NCT07543172Phase 2

CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer

Not Yet Recruiting
NCT04298606Early Phase 1

A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

Completed
NCT06011772Early Phase 1

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Active Not Recruiting
NCT02955290Phase 1

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

Active Not Recruiting

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4